Skip to content
INJECTABLE
PIPZO 1.125 INJ
PIPZO 1.125 INJ
By ALKEM
Best deal on the Internet
Prescription Required
Couldn't load pickup availability
Check Availability
Rapid 3-4 Day Delivery,Tiny Extra Fee!
-
Pet Safe
-
Best Quality
-
Fast Delivery
-
Secure Payment
Collapsible content
About Product
Pipzo Piperacillin and Tazobactam Injection 1.125g, manufactured by Alkem Laboratories Ltd., is a cutting-edge, hospital-grade, broad-spectrum combination antibiotic formulated to address moderate to severe bacterial infections that have proven resistant or difficult to manage with single-agent therapy. The core clinical challenge this product targets is bacterial resistance, specifically the ability of many gram-negative and gram-positive pathogens to produce beta-lactamase enzymes that destroy conventional penicillin-class antibiotics before they can exert their bactericidal action. Pipzo 1.125g resolves this resistance mechanism by pairing a potent anti-pseudomonal penicillin with a clinically proven beta-lactamase inhibitor, restoring and amplifying antibiotic efficacy against a wide spectrum of difficult-to-treat organisms. This injection is administered exclusively in hospital and clinical settings under the direct supervision of a qualified medical professional. Animeal is proud to offer Pipzo Piperacillin and Tazobactam Injection 1.125g as part of our commitment to providing veterinary and medical professionals with access to clinically validated, pharmaceutical-grade therapeutic products that protect the health of patients across species.
Ingredients:
Piperacillin Sodium 1000mg (equivalent to Piperacillin 1g):
Piperacillin is an extended-spectrum ureidopenicillin antibiotic that operates by irreversibly inhibiting transpeptidase enzymes, specifically penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls. These PBPs are responsible for catalysing the final cross-linking step in peptidoglycan synthesis, the structural polymer that maintains bacterial cell wall integrity. By binding to and inactivating PBPs, Piperacillin prevents the formation of this critical scaffold, rendering the bacterial cell wall structurally unstable. The resulting osmotic imbalance causes cellular lysis and bacterial death. Piperacillin demonstrates broad activity against gram-positive organisms including Streptococcus spp. and Staphylococcus spp. (non-beta-lactamase-producing strains), and crucially against gram-negative bacteria including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Haemophilus influenzae. Its anti-pseudomonal activity distinguishes it from narrower penicillins, making it indispensable in the management of nosocomial and polymicrobial infections.
Tazobactam Sodium 125mg (equivalent to Tazobactam 0.125g):
Tazobactam is a triazolylmethyl penicillanic acid sulfone and a potent, irreversible beta-lactamase inhibitor. Many bacteria have evolved the capacity to produce beta-lactamase enzymes, which hydrolyse and inactivate the beta-lactam ring of penicillin-class antibiotics, rendering them therapeutically ineffective. Tazobactam functions as a suicide substrate: it binds with high affinity to beta-lactamase enzymes, forming a stable acyl-enzyme complex that permanently inactivates the enzyme before it can degrade Piperacillin. This mechanism, known as mechanism-based inhibition, is effective against a broad range of beta-lactamases including TEM, SHV, and OXA types produced by gram-negative organisms. By neutralising resistance at the enzymatic level, Tazobactam dramatically extends the spectrum and potency of Piperacillin, allowing it to act against beta-lactamase-producing strains that would otherwise be fully resistant.
Features and Benefits
Destroys Bacterial Resistance Before It Can Pro...
Destroys Bacterial Resistance Before It Can Protect the Pathogen: The defining clinical advantage of Pipzo 1.125g lies in its dual-action formulation, where Tazobactam neutralises the very enzyme bacteria use to escape antibiotic therapy. By eliminating beta-lactamase activity at the molecular level, this combination restores Piperacillin's full bactericidal potency against resistant strains that would otherwise evade single-agent penicillin treatment, making it a preferred choice of infectious disease specialists managing complex, treatment-resistant infections.
Eliminates a Broad Spectrum of Life-Threatening Pathogens: Pipzo 1.125g targets an extensive range of clinically significant gram-positive and gram-negative organisms, including the notoriously difficult Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, and Bacteroides fragilis. This broad bactericidal coverage makes it an invaluable first-line option in empirical therapy for serious nosocomial and community-acquired infections before culture and sensitivity results are available, reducing time to effective treatment and improving patient outcomes.
Reinforces Clinical Outcomes in Critical and Hospitalised Patients: In intensive care, post-surgical, and immunocompromised settings, uncontrolled bacterial infections carry the highest risk of progression to life-threatening sepsis. Pipzo 1.125g targets polymicrobial infections at multiple anatomical sites simultaneously, alleviates the bacterial burden rapidly, and supports faster clinical recovery, reducing the risk of systemic complications and the need for escalation to last-resort antibiotic therapies.
Supports Responsible Antibiotic Use Through Targeted Combination Therapy: By incorporating a beta-lactamase inhibitor rather than simply escalating the antibiotic dose, Pipzo 1.125g aligns with global antimicrobial stewardship principles. This approach maximises bactericidal efficacy while minimising the selection pressure that drives broader antibiotic resistance, ensuring that this powerful combination remains therapeutically relevant for future patient populations.
Pharmaceutical-Grade Sterile Formulation for Safe Intravenous Delivery: Pipzo 1.125g is manufactured as a sterile lyophilised powder for reconstitution, ensuring precise dosing, stability, and patient safety during intravenous administration. The formulation meets rigorous Indian Pharmacopoeia (IP) and international cGMP standards, reflecting Alkem Laboratories' unwavering commitment to injectable product quality at every stage of manufacture.
Usage and Applications
How to Use:Pipzo Piperacillin and Tazobactam In...
How to Use:
Pipzo Piperacillin and Tazobactam Injection 1.125g must be administered exclusively by a qualified physician, nurse, or trained healthcare professional in a hospital, clinic, or critical care setting. This product is not suitable for self-administration under any circumstances. The injection is prepared by reconstituting the sterile powder with an appropriate volume of a compatible diluent such as sterile water for injection or normal saline, as directed by the prescribing physician or institutional protocol. Once reconstituted, the solution is typically administered by slow intravenous infusion over the recommended infusion period. The dose, frequency, and duration of therapy are determined entirely by the treating physician based on the nature, site, and severity of the infection, the patient's renal function, body weight, clinical status, and microbiological culture results. Do not mix Pipzo with other antibiotics or medications in the same infusion line without confirming compatibility. Always complete the full prescribed course of therapy even if clinical improvement is observed earlier, to prevent the development of antibiotic resistance and ensure complete eradication of the infecting organism.
Storage Advice:
Store unopened Pipzo Piperacillin and Tazobactam Injection 1.125g vials in a cool, dry place below 25 degrees Celsius, protected from direct sunlight, moisture, and excessive heat. Do not freeze the unreconstituted product. Once reconstituted, the solution should be used immediately or stored in accordance with the stability guidelines provided in the product insert, typically within 12 hours at room temperature or 48 hours under refrigeration between 2 and 8 degrees Celsius. Discard any unused reconstituted solution after the recommended storage period. This product must be handled and stored in accordance with institutional infection control protocols and pharmaceutical handling standards. Do not use after the expiry date printed on the vial label and outer carton. Keep out of reach of children and unauthorised personnel.
About the Brand:
Alkem Laboratories Ltd. was founded in 1973 by the late Mr. Samprada Singh in Mumbai, India, and has grown over five decades into one of India's top ten pharmaceutical companies, with a presence spanning over 40 countries across the United States, Europe, Australia, Latin America, Africa, the CIS region, and Southeast Asia. The company's manufacturing facilities are approved by leading international regulatory authorities including the US FDA, UK MHRA, and TGA Australia, and operate in full compliance with WHO-GMP and cGMP standards, reflecting a zero-compromise approach to sterility, potency, and pharmaceutical quality. Alkem's research and development philosophy, anchored by over 500 scientists across six global R&D centres, is driven by the principle of "Extended Lifecare Beyond Boundaries," with sustained investment in complex generics, novel formulations, and biosimilars across therapeutic areas including anti-infectives, cardiology, gastroenterology, and CNS. The company's commitment to ethical manufacturing, sustainable healthcare access, and consistent therapeutic innovation aligns with Animeal's commitment to quality, safety, and science-backed solutions for every patient, human or animal. Discover Alkem Laboratories today.
Disclaimer:
Please note that while Pipzo Piperacillin and Tazobactam Injection 1.125g is formulated from Piperacillin Sodium 1000mg and Tazobactam Sodium 125mg and is indicated for the treatment of moderate to severe bacterial infections in adults and paediatric patients under medical supervision, it is a prescription-only injectable antibiotic and must not be purchased, stored, prepared, or administered without a valid prescription from a licensed medical professional. This product is intended exclusively for use in hospital, clinical, or supervised outpatient settings and is not suitable for home administration or self-use under any circumstances. For patients with known hypersensitivity to penicillins, cephalosporins, or other beta-lactam antibiotics, or those with significant renal impairment, the prescribing physician must conduct a thorough clinical assessment and adjust dosing accordingly before initiating therapy. Animeal supports your health and the health of your patients but does not replace the advice of a qualified veterinary or medical professional.
